Added value of whole‐exome and <scp>RNA</scp> sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel — Armelle Dufresne (2024) | RDL Network
Added value of whole‐exome and <scp>RNA</scp> sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel
Article 2024 en
Authors
AD
Armelle Dufresne
VA
Valéry Attignon
AF
Anthony Ferrari
Abstract
1 min read
In advanced and refractory cancer patients in whom no MBTR was recommended from TGP/aCGH, WES/RNA-Seq allowed to identify more alterations which may in turn, in a limited fraction of patients, lead to new MBTR.
Russell J. Diefenbach, Jenny Lee, Dario Strbenac, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Andrew J. Spillane, Jonathan R. Stretch, Robyn P.M. Saw, John F. Thompson, Sydney Ch’ng, Richard A Scolyer, Richard Kefford, Helen Rizos
Meletios A Dimopoulos, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomáš Pika, Sosana Delimpasi, Javier de la Rubia, Ângelo Maiolino, Tony Reiman, Joaquín Martínez‐López, Thomas G. Martin, Joseph Mıkhael, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, Sylvia Marion, Roman Hájek
Discussion(0)
No comments yet. Be the first to comment.